Charles Schwab Investment Management Inc. Raises Stock Position in Precigen, Inc. (NASDAQ:PGEN)

Charles Schwab Investment Management Inc. raised its position in Precigen, Inc. (NASDAQ:PGEN) by 4.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,278,862 shares of the biotechnology company’s stock after purchasing an additional 56,012 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.44% of Precigen worth $1,432,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Iridian Asset Management LLC CT lifted its holdings in Precigen by 38.8% in the fourth quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock valued at $5,871,000 after acquiring an additional 1,465,962 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after purchasing an additional 149,829 shares during the last quarter. State Street Corp lifted its stake in shares of Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after purchasing an additional 29,253 shares during the last quarter. LexAurum Advisors LLC grew its holdings in shares of Precigen by 151.9% during the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 417,055 shares during the period. Finally, FMR LLC increased its position in shares of Precigen by 26.4% during the 3rd quarter. FMR LLC now owns 345,204 shares of the biotechnology company’s stock worth $327,000 after purchasing an additional 72,033 shares during the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Price Performance

Shares of Precigen stock opened at $1.59 on Friday. The stock has a market capitalization of $467.53 million, a price-to-earnings ratio of -2.89 and a beta of 1.58. The business has a 50-day moving average of $1.67 and a 200 day moving average of $1.18. Precigen, Inc. has a 12 month low of $0.65 and a 12 month high of $2.17.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. The business had revenue of $1.19 million during the quarter, compared to analyst estimates of $1.30 million. Equities research analysts anticipate that Precigen, Inc. will post -0.32 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on PGEN shares. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Precigen in a research report on Thursday, March 20th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.